CRISPR Therapeutics Hires Tony Ho From AstraZeneca to Lead R&D

Frank Vinluan

Frank Vinluan

August 4th, 2017

Xconomy Boston —

CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com Follow @frankvinluan

Trending on Xconomy

Underwriters and Partners

Xpertise: Watch + Learn

From Our Editors · Special Report
2019 Blockchain Outlook — Reality Check
Reality Check
Xconomy

From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Facing an Uncertain Future
Xconomy

Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed

From Our Advertisers

Wisconsin helps biotech company raise $20 million
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation

Tweets from https://twitter.com/Xconomy/lists/lifesci